Chloe Gui
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Chloe Gui has a total of 74 co-authors. Here are the top co-authors by number of shared publications:
Vikas Patil
Princess Margaret Cancer Centre, University Health Network , Toronto, Ontario
3 shared publicationsAlexander P Landry
Division of Neurosurgery, Department of Surgery, University of Toronto , Toronto, Ontario
2 shared publicationsAndrew Ajisebutu
Division of Neurosurgery, Department of Surgery, University of Toronto , Toronto, Ontario
2 shared publicationsFarshad Nassiri
Division of Neurosurgery, Department of Surgery, University of Toronto , Toronto, Ontario
2 shared publicationsGelareh Zadeh
Department of Neurosurgery, Mayo Clinic , Rochester (O.S., G.Z.)
2 shared publications- Gelareh Zadeh
Mayo Clinic Department of Neurosurgery Rochester, Minnesota, 55905
2 shared publications
Latest Publications
- Open Access
- 15 March 2026
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 28 (7) , 1727-1740
Modern molecular profiling recontextualizes the NRG/RTOG 0539 trial and reveals hidden high-risk and radiotherapy-resistant meningiomas
Background: Meningiomas exhibit clinical heterogeneity. Radiotherapy (RT) remains the only adjuvant therapy, but tumor-control is variable, and biomarkers are limited. NRG/RTOG-0539 is the first prospective phase 2 trial to stratify meningioma patients for adjuvant RT based on clinical risk. Here, we apply modern molecular tools to this cohort and identify correlates of RT response. Methods: Tumor tissue from 100 RTOG-0539 patients was profiled using DNA methylation arrays, RNA sequencing, and whole-exome sequencing. Recurrence scores, Molecular Groups, gene expression, and copy number alterations were compared across clinical groups and between RT responders and non-responders; non-response was defined as progression or death within 3 years. Results: Modern grading criteria, including brain invasion, TERT mutation, CDKN2A/B deletion, and 1p/1q status, would reclassify 10% of tumors and alter treatment group assignment in 7%. Non-responders to RT exhibited more frequent 1p and 14q loss, and more copy number alterations. Transcriptomic and epigenetic profiling revealed immune-related signatures in responders and cell cycle–related pathways in non-responders, several of which overlapped with targets of vorinostat, a histone deacetylase inhibitor previously validated in aggressive meningioma models. The Proliferative Molecular Group was an independent predictor of post-RT recurrence in multivariable analysis, outperforming WHO grade. Conclusion: Multi-omic analysis of the NRG/RTOG-0539 cohort shows that updated WHO grading criteria, incorporating molecular and cytogenetic features, improve risk stratification. However, molecular classification, particularly the Proliferative group, remains an independent and stronger predictor of RT response. These findings support integrating molecular biomarkers alongside modern grading frameworks to guide treatment and trial design in meningioma. Clinical Trial Information: NCT00895622.
- 15 March 2026
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 28 (7) , 1727-1740
Open AccessModern molecular profiling recontextualizes the NRG/RTOG 0539 trial and reveals hidden high-risk and radiotherapy-resistant meningiomas
Background: Meningiomas exhibit clinical heterogeneity. Radiotherapy (RT) remains the only adjuvant therapy, but tumor-control is variable, and biomarkers are limited. NRG/RTOG-0539 is the first prospective phase 2 trial to stratify meningioma patients for adjuvant RT based on clinical risk. Here, we apply modern molecular tools to this cohort and identify correlates of RT response. Methods: Tumor tissue from 100 RTOG-0539 patients was profiled using DNA methylation arrays, RNA sequencing, and whole-exome sequencing. Recurrence scores, Molecular Groups, gene expression, and copy number alterations were compared across clinical groups and between RT responders and non-responders; non-response was defined as progression or death within 3 years. Results: Modern grading criteria, including brain invasion, TERT mutation, CDKN2A/B deletion, and 1p/1q status, would reclassify 10% of tumors and alter treatment group assignment in 7%. Non-responders to RT exhibited more frequent 1p and 14q loss, and more copy number alterations. Transcriptomic and epigenetic profiling revealed immune-related signatures in responders and cell cycle–related pathways in non-responders, several of which overlapped with targets of vorinostat, a histone deacetylase inhibitor previously validated in aggressive meningioma models. The Proliferative Molecular Group was an independent predictor of post-RT recurrence in multivariable analysis, outperforming WHO grade. Conclusion: Multi-omic analysis of the NRG/RTOG-0539 cohort shows that updated WHO grading criteria, incorporating molecular and cytogenetic features, improve risk stratification. However, molecular classification, particularly the Proliferative group, remains an independent and stronger predictor of RT response. These findings support integrating molecular biomarkers alongside modern grading frameworks to guide treatment and trial design in meningioma. Clinical Trial Information: NCT00895622.
- Open Access
- 18 February 2026
- Published by Oxford University Press (OUP) in Neuro-Oncology Advances
- Vol. 8 (Supplement) , i43-i50
Single-cell transcriptomic profiling of malignant peripheral nerve sheath tumors
Malignant peripheral nerve sheath tumors (MPNSTs) are aggressive sarcomas arising from Schwann cells and characterized by marked cellular and molecular heterogeneity. Although bulk multi-omic studies have provided valuable insights into MPNST biology, recent advances in single-cell profiling have deepened our understanding of the tumor microenvironment and molecular mechanisms underlying malignant transformation. Single cell analyses have revealed distinct Schwann cell-like, malignant neural crest-like, immune, and stromal cellular subpopulations within MPNSTs and their precursor lesions. Comparative profiling of MPNSTs, neurofibromas, and atypical neurofibromatous neoplasms of uncertain biologic potential, suggest that MPNST progression involves Schwann cell dedifferentiation into a more primitive, stem-like state. In this review, we summarize key discoveries from single-cell characterization studies, and discuss how these findings illuminate MPNST tumorigenesis, cellular plasticity, and potential therapeutic vulnerabilities.
- 18 February 2026
- Published by Oxford University Press (OUP) in Neuro-Oncology Advances
- Vol. 8 (Supplement) , i43-i50
Open AccessSingle-cell transcriptomic profiling of malignant peripheral nerve sheath tumors
Malignant peripheral nerve sheath tumors (MPNSTs) are aggressive sarcomas arising from Schwann cells and characterized by marked cellular and molecular heterogeneity. Although bulk multi-omic studies have provided valuable insights into MPNST biology, recent advances in single-cell profiling have deepened our understanding of the tumor microenvironment and molecular mechanisms underlying malignant transformation. Single cell analyses have revealed distinct Schwann cell-like, malignant neural crest-like, immune, and stromal cellular subpopulations within MPNSTs and their precursor lesions. Comparative profiling of MPNSTs, neurofibromas, and atypical neurofibromatous neoplasms of uncertain biologic potential, suggest that MPNST progression involves Schwann cell dedifferentiation into a more primitive, stem-like state. In this review, we summarize key discoveries from single-cell characterization studies, and discuss how these findings illuminate MPNST tumorigenesis, cellular plasticity, and potential therapeutic vulnerabilities.
- Open Access
- 8 November 2025
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 28 (3) , 765-775
Assessment of molecular tools in pediatric, adolescent, and young adult meningioma highlights the need for lifespan precision in neuro-oncology
Background: Adolescent and young adult (AYA) patients remain underrepresented in neuro-oncology research. Despite being the second most common primary brain tumor in this population, meningiomas have not been studied using age-specific molecular analyses. DNA methylation-based classification and prognostic tools have transformed meningioma care. This study aimed to evaluate the performance of these tools across age groups. Methods: We analyzed 1,568 meningiomas with DNA methylation and clinical data, including 18 pediatric patients (39 years). Pediatric and AYA (P/AYA) tumors were combined and compared with adult tumors. The performance of established molecular classifiers and recurrence predictors, as well as differences in chromosomal copy number alterations were compared across age groups. Results: While histologic grading was comparable between cohorts, P/AYA tumors displayed significantly fewer aggressive molecular groups and lower frequencies of chromosomal arm losses, including 1p, 6q, and 14q. The adult-trained recurrence predictor failed in the P/AYA population (AUC 0.57), despite similar score distributions. Retraining the model on an age-specific cohort using an identical analytic framework improved performance (AUC 0.79) and enabled effective stratification of progression-free survival (P = 0.00054). Importantly, 1p loss retained prognostic significance within the P/AYA group, supporting its clinical utility. Conclusions: Molecular tools developed in adult-dominant cohorts do not generalize to younger patients due to both biological divergence and exclusion from model development. These findings underscore the need for age-specific molecular frameworks and highlight the imperative of including P/AYA populations in precision neuro-oncology research to ensure lifespan-equitable care.
- 8 November 2025
- Published by Oxford University Press (OUP) in Neuro-Oncology
- Vol. 28 (3) , 765-775
Open AccessAssessment of molecular tools in pediatric, adolescent, and young adult meningioma highlights the need for lifespan precision in neuro-oncology
Background: Adolescent and young adult (AYA) patients remain underrepresented in neuro-oncology research. Despite being the second most common primary brain tumor in this population, meningiomas have not been studied using age-specific molecular analyses. DNA methylation-based classification and prognostic tools have transformed meningioma care. This study aimed to evaluate the performance of these tools across age groups. Methods: We analyzed 1,568 meningiomas with DNA methylation and clinical data, including 18 pediatric patients (39 years). Pediatric and AYA (P/AYA) tumors were combined and compared with adult tumors. The performance of established molecular classifiers and recurrence predictors, as well as differences in chromosomal copy number alterations were compared across age groups. Results: While histologic grading was comparable between cohorts, P/AYA tumors displayed significantly fewer aggressive molecular groups and lower frequencies of chromosomal arm losses, including 1p, 6q, and 14q. The adult-trained recurrence predictor failed in the P/AYA population (AUC 0.57), despite similar score distributions. Retraining the model on an age-specific cohort using an identical analytic framework improved performance (AUC 0.79) and enabled effective stratification of progression-free survival (P = 0.00054). Importantly, 1p loss retained prognostic significance within the P/AYA group, supporting its clinical utility. Conclusions: Molecular tools developed in adult-dominant cohorts do not generalize to younger patients due to both biological divergence and exclusion from model development. These findings underscore the need for age-specific molecular frameworks and highlight the imperative of including P/AYA populations in precision neuro-oncology research to ensure lifespan-equitable care.
- 1 January 2024
- Published by Springer Nature
- p. 19-23
Advancement in Genetic and Molecular Landscape of Peripheral Nerve Sheath Tumors
- 1 January 2024
- Published by Springer Nature
- p. 19-23
Advancement in Genetic and Molecular Landscape of Peripheral Nerve Sheath Tumors
- Open Access
- 12 July 2023
- Published by Cambridge University Press (CUP) in Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques
- Vol. 51 (3) , 362-368
Methylation Profiling Identifies Stability of Isocitrate Dehydrogenase Mutation Over Time
Objective: Isocitrate dehydrogenase (IDH) mutation status is a key diagnostic and prognostic feature of gliomas. It is thought to occur early in glioma tumorigenesis and remain stable over time. However, there are reports documenting a loss of IDH mutation status in a subset of patients with glioma recurrence. Here, we identified patients with a documented loss of IDH mutation status longitudinally and performed multi-platform analysis in order to determine if IDH mutations are stable throughout glioma evolution. Methods: We retrospectively identified patients from our institution from 2009 to 2018 with immunohistochemistry (IHC)-recorded IDH mutation status changes longitudinally. Archived formalin-fixed paraffin-embedded and frozen tissue samples from these patients were collected from our institution’s tumour bank. Samples were analysed using methylation profiling, copy number variation, Sanger sequencing, droplet digital PCR (ddPCR) and IHC. Results: We reviewed 1491 archived glioma samples including 78 patients with multiple IDH mutant tumour samples collected longitudinally. In all instances of documented loss of IDH mutation status, multi-platform profiling identified a mixture of low tumour cell content and non-neoplastic tissue including perilesional, reactive or inflammatory cells. Conclusions: All patients with a documented loss of IDH mutation status longitudinally were resolved through multi-platform analysis. These findings support the hypothesis that IDH mutations occur early in gliomagenesis and in the absence of copy number changes at the IDH loci and are stable throughout tumour treatment and evolution. Our study highlights the importance of accurate surgical sampling and the role of DNA methylome profiling in diagnostically uncertain cases for integrated pathological and molecular diagnosis.
- 12 July 2023
- Published by Cambridge University Press (CUP) in Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques
- Vol. 51 (3) , 362-368
Open AccessMethylation Profiling Identifies Stability of Isocitrate Dehydrogenase Mutation Over Time
Objective: Isocitrate dehydrogenase (IDH) mutation status is a key diagnostic and prognostic feature of gliomas. It is thought to occur early in glioma tumorigenesis and remain stable over time. However, there are reports documenting a loss of IDH mutation status in a subset of patients with glioma recurrence. Here, we identified patients with a documented loss of IDH mutation status longitudinally and performed multi-platform analysis in order to determine if IDH mutations are stable throughout glioma evolution. Methods: We retrospectively identified patients from our institution from 2009 to 2018 with immunohistochemistry (IHC)-recorded IDH mutation status changes longitudinally. Archived formalin-fixed paraffin-embedded and frozen tissue samples from these patients were collected from our institution’s tumour bank. Samples were analysed using methylation profiling, copy number variation, Sanger sequencing, droplet digital PCR (ddPCR) and IHC. Results: We reviewed 1491 archived glioma samples including 78 patients with multiple IDH mutant tumour samples collected longitudinally. In all instances of documented loss of IDH mutation status, multi-platform profiling identified a mixture of low tumour cell content and non-neoplastic tissue including perilesional, reactive or inflammatory cells. Conclusions: All patients with a documented loss of IDH mutation status longitudinally were resolved through multi-platform analysis. These findings support the hypothesis that IDH mutations occur early in gliomagenesis and in the absence of copy number changes at the IDH loci and are stable throughout tumour treatment and evolution. Our study highlights the importance of accurate surgical sampling and the role of DNA methylome profiling in diagnostically uncertain cases for integrated pathological and molecular diagnosis.
- Open Access
Detection of local growth patterns in longitudinally imaged low-grade gliomas
Background Diffuse low-grade gliomas (LGGs) are primary brain tumors with infiltrative, anisotropic growth related to surrounding white and grey matter structures. In this study, we illustrate the use of deformation-based morphometry (DBM) as a simple and objective method to study the local change in growth patterns of LGGs. Methods An imaging pipeline was developed involving the creation of patient-specific average templates and nonlinear registration of pre-treatment follow-up MRIs to the average template. Jacobian maps were derived and analyzed to identify areas of tissue expansion and contraction over time. Results Our analysis demonstrates that tissue expansion occurs primarily around the edges of the tumor, while the lesion core and areas adjacent to obstacles, such as the skull, show no significant growth. Tumors also appeared to grow faster and predominantly in areas of white matter. Regions of the brain surrounding the lesion showed slight contraction over time, likely representing compression due to mass effect of the tumor. Conclusions We demonstrate that DBM is a useful clinical tool to understand the long-term clinical course of an individual’s tumor and identify areas of rapid growth, which can explain the clinical signs and symptoms, predict future symptoms, and guide targeted diagnostics and therapy. Highlights Low-grade glioma expansion occurs primarily around the edges of the tumor. Tumor cores and tissue next to obstacles show no significant growth over time. DBM provides a clinically valuable assessment of local tumor growth and activity.
Open AccessDetection of local growth patterns in longitudinally imaged low-grade gliomas
Background Diffuse low-grade gliomas (LGGs) are primary brain tumors with infiltrative, anisotropic growth related to surrounding white and grey matter structures. In this study, we illustrate the use of deformation-based morphometry (DBM) as a simple and objective method to study the local change in growth patterns of LGGs. Methods An imaging pipeline was developed involving the creation of patient-specific average templates and nonlinear registration of pre-treatment follow-up MRIs to the average template. Jacobian maps were derived and analyzed to identify areas of tissue expansion and contraction over time. Results Our analysis demonstrates that tissue expansion occurs primarily around the edges of the tumor, while the lesion core and areas adjacent to obstacles, such as the skull, show no significant growth. Tumors also appeared to grow faster and predominantly in areas of white matter. Regions of the brain surrounding the lesion showed slight contraction over time, likely representing compression due to mass effect of the tumor. Conclusions We demonstrate that DBM is a useful clinical tool to understand the long-term clinical course of an individual’s tumor and identify areas of rapid growth, which can explain the clinical signs and symptoms, predict future symptoms, and guide targeted diagnostics and therapy. Highlights Low-grade glioma expansion occurs primarily around the edges of the tumor. Tumor cores and tissue next to obstacles show no significant growth over time. DBM provides a clinically valuable assessment of local tumor growth and activity.
- Open Access
- 12 March 2019
- Published by University of Western Ontario, Western Libraries in University of Western Ontario Medical Journal
- Vol. 87 (2) , 59-61
Brain controlled robotic arms - advancements in prosthetic technology
A prosthesis is a medical tool used to replace a missing body part. They are designed to restore both functionality and form to the patient user. There has been a rich history in the field or prosthetics extending back centuries. However, recent advancements have led to the development of more sophisticated and innovative prosthetic technology, such as the brain controlled myoelectric prosthetic limb. While current prosthesis options such as the passive prosthetic and body-powered prosthetic have their respective limitations, the myoelectric prosthetic limb offers an unheralded level of functionality for patients. This article will seek to discuss current and ongoing advancements in the field of prosthetics, with specific regards to artificial limbs. There will be discussion of the history of prosthesis and current prosthesis options for patients, with assessment of their respective benefits and limitations.
- 12 March 2019
- Published by University of Western Ontario, Western Libraries in University of Western Ontario Medical Journal
- Vol. 87 (2) , 59-61
Open AccessBrain controlled robotic arms - advancements in prosthetic technology
A prosthesis is a medical tool used to replace a missing body part. They are designed to restore both functionality and form to the patient user. There has been a rich history in the field or prosthetics extending back centuries. However, recent advancements have led to the development of more sophisticated and innovative prosthetic technology, such as the brain controlled myoelectric prosthetic limb. While current prosthesis options such as the passive prosthetic and body-powered prosthetic have their respective limitations, the myoelectric prosthetic limb offers an unheralded level of functionality for patients. This article will seek to discuss current and ongoing advancements in the field of prosthetics, with specific regards to artificial limbs. There will be discussion of the history of prosthesis and current prosthesis options for patients, with assessment of their respective benefits and limitations.
- 13 February 2019
- Published by Springer Nature in Acta Neurochirurgica
- Vol. 161 (3) , 569-576
Radiology reporting of low-grade glioma growth underestimates tumor expansion
An important aspect in the management of patients with diffuse low-grade gliomas (LGGs) involves monitoring the lesions via serial magnetic resonance imaging (MRI). However, radiological interpretations of LGG interval scans are often qualitative and thus difficult to use clinically.
- 13 February 2019
- Published by Springer Nature in Acta Neurochirurgica
- Vol. 161 (3) , 569-576
Radiology reporting of low-grade glioma growth underestimates tumor expansion
An important aspect in the management of patients with diffuse low-grade gliomas (LGGs) involves monitoring the lesions via serial magnetic resonance imaging (MRI). However, radiological interpretations of LGG interval scans are often qualitative and thus difficult to use clinically.